“Currently, less than 2% of individuals with obesity in the U.S. receive obesity medication and Wegovy in a pill may also ...

Novo Nordisk ( NVO 6.38%) -- the original Ozempic stock -- jumped higher again Thursday after announcing results from a ...

The Novo Nordisk RTO mandate could be a strategy to encourage attrition, but if community-building is the goal, additional ...

Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, ...

Wegovy has been a hugely popular treatment since the Food and Drug Administration (FDA) approved it for weight loss in ...

Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.

Novo Nordisk might be down but it's not out of the weight-loss drug race. The Danish maker of blockbuster drug Wegovy has had ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The struggling Danish company says it looks to reorganize, with the impact on North Carolina workers still unclear.

Novo Nordisk , looking to turn around slowing growth of its blockbuster weight-loss drug Wegovy, plans to test whether its ...